(Yicai Global) March 5 -- Sansure Biotech, a Chinese firm that has manufactured 4 million coronavirus test kits as of the end of last month, has applied to go public on the Shanghai's Star Market for innovative science and technology firms.

Regulators have already accepted the application, the Shanghai Stock Exchange said online yesterday.

Hunan province-based Sansure, one of the first six firms China approved to sell detection kits for Covid-19, hopes to raise CNY557 million (USD80.4 million) via the listing.

The company has shifted millions of its nucleic acid test kits to more than 30 provincial-level regions in China, including 540,000 to the disease's epicenter Hubei, and nearly 100,000 overseas. It also produced detection kits for other coronaviruses, like Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome, African swine fever, Ebola, Zika, avian influenza and the dengue virus.

Founded in 2008, Sansure became profitable in 2018 when it made CNY6.8 million (USD975,000) on revenue of CNY303 million. It multiplied that almost six times to CNY39.5 million in 2019, with revenue rising just 20.4 percent to CNY365 million.

Editor: James Boynton